Srishyla Goverdhana Ravi Sunkoji

Srishyla Goverdhana Ravi Sunkoji

Director Additional Director DIN 08245115
DIN 08245115 First appointment Oct 2018 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 1 historical roles
Total affiliations 1 Since Oct 2018
Shareholding value β€’β€’β€’β€’ Premium profile

About Srishyla Goverdhana Ravi Sunkoji

Data last updated:

Srishyla Goverdhana Ravi Sunkoji was an Additional Director at Adept Pharma And Bioscience Excellence Private Limited (2018–2019). The company operates in Pharma.

DIN 08245115
Primary Designation Additional Director
Industry Pharma
First Appointment 03 Oct 2018

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Additional Director03 Oct 20182012₹6.77 Cr (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Adept Pharma And Bioscience Excellence Private Limited
Premium access

Shareholding and investment profile for Srishyla Goverdhana Ravi Sunkoji

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Srishyla Goverdhana Ravi Sunkoji

Srishyla Goverdhana Ravi Sunkoji was first appointed on 03 Oct 2018 as Additional Director at Adept Pharma And Bioscience Excellence Private Limited.

Srishyla Goverdhana Ravi Sunkoji held 1 earlier board appointment: Adept Pharma And Bioscience Excellence Private Limited (Additional Director, 03 Oct 2018 to 27 Dec 2019).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available